Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study.

Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, Manhes H

Fertility and sterility1 Apr 2002Cited by 99 (Europe PMC)

PMID11937116DOI10.1016/s0015-0282(01)03270-8PepBankPUB-11937116

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women after endometriosis surgery, efficacy did not differ significantly between triptorelin and dienogest.
In plain wordsIn women after endometriosis surgery, efficacy did not differ significantly between triptorelin and dienogest.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEndometriosis efficacy
Study
n = 120
Comparator
Dienogest 1 mg daily
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
3.75 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Statistical analysis of efficacy was not significantly different between the two groups.
5 context sentences(design, population, supporting numbers)
Summary · context
A change in the patient's Revised American Fertility Society score at the post-treatment laparoscopy.
Summary · context
Multicenter, open, randomized, parallel-group clinical trial.
Summary · context
Women with grade 2, 3, and 4 (</=70) endometriosis at initial laparoscopy.
Summary · context
We provided 16 weeks of treatment with Dienogest, 1 mg tablet daily; or with Decapeptyl, 3.75 mg IM injection every 4 weeks.
Summary · context
After exclusion for major protocol deviations, 59 patients were included in the Dienogest group and 61 in the Decapeptyl group.
Report a problemFND-1193711601
02HumanRandomized controlled trialSafety outcome
In women after endometriosis surgery, adverse events occurred in 85.1% with triptorelin and 87.7% with dienogest.
In plain wordsIn women after endometriosis surgery, 85.1% reported adverse events with triptorelin, compared with 87.7% with dienogest.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedPatients reporting adverse events
Study
n = 120
Comparator
Dienogest 1 mg daily
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Measurements
Adverse events
85.1%
Decapeptyl
Adverse events
87.7%
Dienogest
Source sentences
Summary
Adverse events were reported by 87.7% of patients in the Dienogest group and 85.1% in the Decapeptyl group.
4 context sentences(design, population, supporting numbers)
Summary · context
Multicenter, open, randomized, parallel-group clinical trial.
Summary · context
Women with grade 2, 3, and 4 (</=70) endometriosis at initial laparoscopy.
Summary · context
We provided 16 weeks of treatment with Dienogest, 1 mg tablet daily; or with Decapeptyl, 3.75 mg IM injection every 4 weeks.
Summary · context
After exclusion for major protocol deviations, 59 patients were included in the Dienogest group and 61 in the Decapeptyl group.
Report a problemFND-1193711602
03HumanRandomized controlled trialSafety outcome
In women after endometriosis surgery, neither triptorelin nor dienogest affected body weight.
In plain wordsIn women after endometriosis surgery, neither triptorelin nor dienogest changed body weight.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBody weight
Study
n = 61
Comparator
Pretreatment
Outcome group
Body weight · Metabolic and weight
Studied dose
3.75 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Neither treatment affected patient body weight or vital signs.
4 context sentences(design, population, supporting numbers)
Summary · context
Multicenter, open, randomized, parallel-group clinical trial.
Summary · context
Women with grade 2, 3, and 4 (</=70) endometriosis at initial laparoscopy.
Summary · context
We provided 16 weeks of treatment with Dienogest, 1 mg tablet daily; or with Decapeptyl, 3.75 mg IM injection every 4 weeks.
Summary · context
After exclusion for major protocol deviations, 59 patients were included in the Dienogest group and 61 in the Decapeptyl group.
Report a problemFND-1193711603
04HumanRandomized controlled trialSafety outcome
In women after endometriosis surgery, neither triptorelin nor dienogest affected vital signs.
In plain wordsIn women after endometriosis surgery, neither triptorelin nor dienogest changed vital signs.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeVital signs
Study
n = 61
Comparator
Pretreatment
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Neither treatment affected patient body weight or vital signs.
4 context sentences(design, population, supporting numbers)
Summary · context
Multicenter, open, randomized, parallel-group clinical trial.
Summary · context
Women with grade 2, 3, and 4 (</=70) endometriosis at initial laparoscopy.
Summary · context
We provided 16 weeks of treatment with Dienogest, 1 mg tablet daily; or with Decapeptyl, 3.75 mg IM injection every 4 weeks.
Summary · context
After exclusion for major protocol deviations, 59 patients were included in the Dienogest group and 61 in the Decapeptyl group.
Report a problemFND-1193711604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.